PSA Tumors

Proteins from semen as a potential source of information provide information. Prostate cancer is the second most common cancer of men worldwide. But long since not all prostate cancer is associated with a poor prognosis, which requires immediate intervention. There is, therefore, a major challenge to the diagnosis of prostate cancer, to distinguish between aggressive non-aggressive tumors. Currently, but still no procedure provides the necessary security. Scientists of the Urology Clinic of the University Hospital Leipzig AoR ( have identified ejaculate as a potential source of information for detecting aggressive prostate tumors in cooperation with the Hanoverian biotechnology company of mosaiques diagnostics ( Now, the results of their study were published in the current issue of the prestigious journal PLoS one: article/info%3Adoi%2F10.1371%2Fjournal.pone.0067514 In the study were using a special protein-analysis of ejaculate first specific markers for the diagnosis of Prostate cancer are identified. In a further step, the scientists succeeded in identifying 11 protein marker for the first time allow a distinction between the aggressive form of prostate cancer and a slowly growing tumor.

With a sensitivity of 80% and a specificity of 82%, protein analysis in the ejaculate allows a very high reliability in the differentiation of the tumor stage. Although in this respect still no real alternative to the tissue extraction from the prostate, the results of our study are very promising and could enable also a clear recommendation of the therapy in the future in addition to a specific diagnosis”, summarizes Dr. Neuhaus the results of the study. So far a combination of PSA test (prostate specific antigen), palpation, number of positive samples and the determination of the so-called Gleason value was used after the removal of tissue, to identify aggressive prostate tumors. However, slightly elevated PSA levels between 4 and 10 ng/ml and moderate show the majority of the discovered tumors Gleason values between 6 and 7, which greatly complicates a treatment decision. Tissue sampling be carried out to determine the value of the Gleason invasive, ejaculate, however, can be easily and without intervening measures to win. A clear added value on our way to more and more patient-friendly Diagnostics”, explains Dr. Eric Schiffer mosaiques Diagnostics.

Reference Neuhaus J, Schiffer E, Wilcke P, Bauer HW, Leung H, Siwy Ulrici W, p U, J, LC, Horn Santana J seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease PLoS ONE 8(6): e67514. DOI:10.1371/journal.Pone.0067514 about mosaiques diagnostics: A leading biotech company in the area of clinical analysis of protein in the urine (UPA), mosaiques diagnostics recognized cooperation partner of renowned university hospitals all over the world is. The UPA test is subject to over 60 multicenter studies, including several EU consortia. 155 Publications in high-ranking, international journals have appeared to a few years. Under the diagnostic tests for different diseases on the market the brand name DiPat ( are available. They are suitable in particular for the early detection of chronic kidney disease (CKD), such as the diabetic nephropathy (DN), as well as for coronary heart disease (CHD). Thus, the protein analysis is predestined to implement evidence-based, personalized treatments in patients with diabetes mellitus effectively.